AustinPx Invests in Pharmaceutics and Manufacturing Capabilities to Accelerate Drug Development
Retrieved on:
Monday, April 8, 2024
The latest investments enhance AustinPx’s early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.
Key Points:
- The latest investments enhance AustinPx’s early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.
- The technology enables rapid transition into first-in-human clinical trial material manufacturing, while also reducing the cost of drug product development.
- “These tools enable scientists and engineers to rapidly develop life-changing therapies with enhanced data and quality.”
The expanded capabilities are now available for use. - The additional capabilities mark another milestone in the growth of AustinPx’s formulation development and manufacturing offerings, as the Company continues to position itself as a leading CDMO in the pharmaceutical industry.